Daclizumab für die schubförmige Multiple Sklerose

Translated title of the contribution: Evaluation of daclizumab for relapsing multiple sclerosis

S. Faissner, A. Chan

Research output: Contribution to journalArticlepeer-review


Multiple sclerosis is a multifactorial disease of the central nervous system characterized by an autoimmune reaction against myelin with consecutive neurodegeneration and associated neurological impairment. Until now more than ten medications received market authorization. Daclizumab is a monoclonal antibody directed against the IL-2 alpha subunit (CD25) which recently received market authorization for relapsing multiple sclerosis. We will review the potential mechanisms of action, pivotal clinical trial data, side effect profile and the significance for multiple sclerosis therapy.

Translated title of the contributionEvaluation of daclizumab for relapsing multiple sclerosis
Original languageGerman
Pages (from-to)714-718
Number of pages5
JournalTagliche Praxis
Issue number4
StatePublished - 2018
Externally publishedYes


  • Cd56 natural killer cells
  • Daclizumab
  • Disease modifying therapy
  • IL-2
  • Immunomodulatory therapy
  • Relapsing multiple sclerosis


Dive into the research topics of 'Evaluation of daclizumab for relapsing multiple sclerosis'. Together they form a unique fingerprint.

Cite this